84 related articles for article (PubMed ID: 20801048)
41. Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features.
Malo M; Brive L; Luthman K; Svensson P
ChemMedChem; 2010 Feb; 5(2):232-46. PubMed ID: 20077461
[TBL] [Abstract][Full Text] [Related]
42. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
43. Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone.
Thorn DA; Siemian JN; Zhang Y; Li JX
Psychopharmacology (Berl); 2015 Sep; 232(18):3309-18. PubMed ID: 26037946
[TBL] [Abstract][Full Text] [Related]
44. Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats.
Thorn DA; Zhang Y; Li JX
Br J Pharmacol; 2016 Apr; 173(8):1363-72. PubMed ID: 26776953
[TBL] [Abstract][Full Text] [Related]
45. A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus.
Mammoli V; Bonifazi A; Dal Ben D; Giannella M; Giorgioni G; Piergentili A; Pigini M; Quaglia W; Thomas A; Newman AH; Ferré S; Sanchez-Soto M; Keck TM; Del Bello F
ChemMedChem; 2016 Aug; 11(16):1819-28. PubMed ID: 26990230
[TBL] [Abstract][Full Text] [Related]
46. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study.
Nikolic K; Veljkovic N; Gemovic B; Srdic-Rajic T; Agbaba D
Comb Chem High Throughput Screen; 2013 May; 16(4):298-319. PubMed ID: 23360165
[TBL] [Abstract][Full Text] [Related]
47. Isothiocyanatobenzyl imidazoline is an alkylating agent for I2-imidazoline binding sites in rat and rabbit tissues.
Boronat MA; Olmos G; Miller DD; Patil PN; García-Sevilla JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):351-5. PubMed ID: 9550309
[TBL] [Abstract][Full Text] [Related]
48. Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.
Kimura A; Tyacke RJ; Robinson JJ; Husbands SM; Minchin MC; Nutt DJ; Hudson AL
Brain Res; 2009 Jul; 1279():21-8. PubMed ID: 19410564
[TBL] [Abstract][Full Text] [Related]
49. Effects of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) on dopamine synthesis in rat striatum in vivo.
Sastre-Coll A; Esteban S; García-Sevilla JA
Ann N Y Acad Sci; 1999 Jun; 881():364. PubMed ID: 10415937
[No Abstract] [Full Text] [Related]
50. Behavioral effects of the imidazoline I(2) receptor ligand BU99006 in rats.
Qiu Y; Thorn DA; Zhang Y; He X; Li JX
Behav Pharmacol; 2014 Apr; 25(2):130-6. PubMed ID: 24518265
[TBL] [Abstract][Full Text] [Related]
51. 2-(4,5-dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I(2) imidazoline receptor ligands.
Saczewski F; Hudson AL; Tyacke RJ; Nutt DJ; Man J; Tabin P; Saczewski J
Eur J Pharm Sci; 2003 Oct; 20(2):201-8. PubMed ID: 14550886
[TBL] [Abstract][Full Text] [Related]
52. Protective effect of the imidazoline I2 receptor agonist 2-BFI on oxidative cytotoxicity in astrocytes.
Choi DH; Yun JH; Lee J
Biochem Biophys Res Commun; 2018 Sep; 503(4):3011-3016. PubMed ID: 30143255
[TBL] [Abstract][Full Text] [Related]
53. Exploring the antidepressant-like potential of the selective I
Hernández-Hernández E; García-Sevilla JA; García-Fuster MJ
Pharmacol Rep; 2021 Feb; 73(1):288-295. PubMed ID: 32748254
[TBL] [Abstract][Full Text] [Related]
54. Tritium labelling and characterization of the potent imidazoline I1 receptor antagonist [5,7-3H] (+/-)-efaroxan at high specific activity.
Egan JA; Filer CN
Appl Radiat Isot; 2003 Jun; 58(6):675-7. PubMed ID: 12798376
[TBL] [Abstract][Full Text] [Related]
55. Gender difference in epileptogenic effects of 2-BFI and BU224 in mice.
Min JW; Peng BW; He X; Zhang Y; Li JX
Eur J Pharmacol; 2013 Oct; 718(1-3):81-6. PubMed ID: 24055191
[TBL] [Abstract][Full Text] [Related]
56. Modulation of in-membrane receptor clustering upon binding of multivalent ligands.
Grochmal A; Ferrero E; Milanesi L; Tomas S
J Am Chem Soc; 2013 Jul; 135(27):10172-7. PubMed ID: 23763669
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
Ye XY; Morales CL; Wang Y; Rossi KA; Malmstrom SE; Abousleiman M; Sereda L; Apedo A; Robl JA; Miller KJ; Krupinski J; Wacker DA
Bioorg Med Chem Lett; 2014 Jun; 24(11):2539-45. PubMed ID: 24755425
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and biological activities of novel furo[2,3,4-jk][2]benzazepin-4(3H)-one derivatives.
Ando K; Akai Y; Kunitomo J; Yokomizo T; Nakajima H; Takeuchi T; Yamashita M; Ohta S; Ohishi T; Ohishi Y
Org Biomol Chem; 2007 Feb; 5(4):655-63. PubMed ID: 17285174
[TBL] [Abstract][Full Text] [Related]
59. Imidazoline scaffold in medicinal chemistry: a patent review (2012-2015).
Sączewski F; Kornicka A; Balewski Ł
Expert Opin Ther Pat; 2016 Sep; 26(9):1031-48. PubMed ID: 27382975
[TBL] [Abstract][Full Text] [Related]
60. Application of comparative molecular field analysis to dopamine D2 partial agonists.
McGaughey GB; Mewshaw RE
Bioorg Med Chem; 1999 Nov; 7(11):2453-6. PubMed ID: 10632054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
